Biostock Investor Meeting Interview With Elicera Therapeutics Yo Elicera therapeutics, led by ceo jamal el mosleh, is developing immuno oncology drug candidates based primarily on oncolytic viruses and car t cells. the product portfolio includes four drug candidates and the company has also developed the technology platform itank . Biostock interviews jamal el mosleh, ceo at elicera therapeutics, at biostock investor meeting in september 2022.0:00 welcome0:15 elicera's main goal0:26 why.
Biostock Investor Meeting Interview With Elicera Therapeutics ођ Gothenburg based elicera therapeutics, headed by ceo jamal el mosleh, travelled to stockholm to present the company at the biostock investor meeting. the cell and gene therapy company has developed a universal car t cell enhancement technology platform called itank (immunotherapies activated with nap for efficient killing) to be used in the. Jamal el mosleh, ceo of elicera therapeutics, presents the company at biostock investor meeting in september 2022.0:00 introduction to elicera therapeutics1:. Biostock investor meeting: interview with elicera therapeutics tue, sep 27, 2022 08:45 cet report this content elicera therapeutics, led by ceo jamal el mosleh, is developing immuno oncology drug candidates based primarily on oncolytic viruses and car t cells. 31 may, 2021gothenburg based elicera therapeutics develops a portfolio of drug candidates helping the immune system in the fight against various forms of cancer. the share is about to be listed on nasdaq first north growth market, and the company aims to raise 52 msek to drive the development of its drug candidates and the technology […].
Comments are closed.